Device Trial Radar · NCT05889390
Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
71
Actual
Start
Feb 20, 2023
Primary completion
Oct 31, 2025
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Semmelweis UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.
Conditions
- HER2-negative Breast Cancer
Interventions
Oncotherm EHY-2030Device
Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.
PaclitaxelDrug
weekly paclitaxel for 12 weeks
CarboplatinDrug
added to weekly paclitaxel if patient has triple-negative breast cancer
Cyclophosphamide/DoxorubicinDrug
according to the AC protocol
Breast cancer removal surgeryProcedure
Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Residual size of the primary tumor, determined by imaging techniques (in percentage)Time frame: change from baseline at 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University
Budapest, Budapest, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.